What are the limitations of EUS in pancreatic cancer? In CP, the diagnostic accuracy of EUS-FNA for pancreatic masses falls to approximately 54% to 73%. As mentioned previously, visualization of SMA and SMV invasion is limited with EUS.
How is EUS used in the diagnosis and staging of pancreatic cancer? EUS-FNA is the preferred diagnostic procedure for pancreatic cancer with a sensitivity of 80% to 85% and specificity near 100%. This compares favorably with CT-guided FNA, with a sensitivity of 62% to 81%. Accuracy of locoregional staging is comparable for CT, MRI, and …
How is EUS used in the diagnosis and staging of pancreatic cancer Read More »
Limitations of EUS for rectal cancer staging • Invasion into the mesorectal fascia cannot be evaluated. • Distinguishing peritumoral inflammation from tumor extension may be difficult. • Staging stenotic rectal masses may be limited. • Posttreatment staging is inaccurate. • Endosonographer experience affects accuracy of staging.
Accuracy of EUS and endorectal coil MRI in staging rectal cancer EUS and MRI appear overall comparable with T stage accuracy for both, ranging from 65% to 95% and nodal stage accuracy of approximately 75%. However, MRI cannot reliably identify T1 tumors, whereas EUS tends to understage T4 tumors. The addition of FNA may increase …
Accuracy of EUS and endorectal coil MRI in staging rectal cancer Read More »
What EUS findings predict malignancy in thickened gastric folds? Definitive diagnosis of thickened gastric folds is difficult despite the use of EUS. These EUS findings are more predictive of malignancy: thickened submucosa, muscularis propria, or serosa; presence of ascites or lymphadenopathy. The etiologic factors of gastric wall thickening caused by thickened mucosa or deep mucosa …
What EUS findings predict malignancy in thickened gastric folds Read More »
What is the role of EUS in gastric cancer staging? Treatment for gastric cancer is stage dependent with endoscopic mucosal resection and submucosal dissection an option for T1N0 cancers and neoadjuvant treatment administered for T3/T4 and nodal positive cancers. Therefore accurate staging is important. If no distant metastatic disease is visible on computed tomography (CT) …
How does EUS affect management of esophageal cancer? In 29% to 56% of cases, EUS findings changed management of esophageal cancer by determining candidates for surgical and endoscopic resection versus neoadjuvant chemoradiation.